Sensorion SA (EPA:ALSEN)

Market Cap	198.23M +14.2%
Revenue (ttm)	5.65M -12.8%
Net Income	-28.09M
EPS	-0.09
Shares Out	300.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,693,130
Average Volume	4,141,773
Open	0.6700
Previous Close	0.7000
Day's Range	0.6140 - 0.8080
52-Week Range	0.1544 - 0.8080
Beta	0.55
RSI	77.58
Earnings Date	Mar 16, 2026

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 68
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALSEN

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.